Julie Burgess
Comptroller/Controller/Auditor presso DESIGN THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Julie Burgess
Società | Posizione | Inizio | Fine |
---|---|---|---|
DESIGN THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 13/09/2021 | - |
San Diego Athena
San Diego Athena Miscellaneous Commercial ServicesCommercial Services San Diego Athena operates as a not-for-profit organization. It supports and develops women. The company was founded by Barbara Bry in 1998 and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Julie Burgess
Precedenti posizioni note di Julie Burgess
Società | Posizione | Inizio | Fine |
---|---|---|---|
OTONOMY | Direttore Amministrativo | 01/01/2014 | 01/04/2021 |
Corporate Officer/Principal | 01/04/2021 | 01/09/2021 | |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | 01/03/2012 | 01/10/2013 |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Comptroller/Controller/Auditor | - | - |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | - | - |
Formazione di Julie Burgess
San Diego State University | Masters Business Admin |
University of California, Santa Barbara | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Comptroller/Controller/Auditor | 3 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Settori
Health Technology | 5 |
Commercial Services | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
DESIGN THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
San Diego Athena
San Diego Athena Miscellaneous Commercial ServicesCommercial Services San Diego Athena operates as a not-for-profit organization. It supports and develops women. The company was founded by Barbara Bry in 1998 and is headquartered in San Diego, CA. | Commercial Services |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
Otonomy, Inc.
Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Julie Burgess
- Esperienza